Business Context and Reporting Period
This Form 8-K Current Report was filed by Sino-Global Shipping America, Ltd. on December 12, 2018, covering events occurring on December 10, 2018. The filing details the closing of a private placement transaction and an amendment to a previously announced Share Purchase Agreement.
Key Financial Metrics
- Capital Raised: $500,000 in aggregate gross proceeds.
- Shares Issued: 420,168 shares of Common Stock.
- Purchase Price: $1.19 per share.
- Ownership Stake: Approximately 3.1% of issued and outstanding shares on a pre-transaction basis.
- Liquidity/Debt: The filing text does not provide specific data on overall company liquidity, debt levels, or operating cash flow.
Material Changes
The primary material change is the reduction of the transaction size. Originally, on November 14, 2018, the Company agreed to raise $1,000,000. On December 10, 2018, the Company and the Investor entered into an Amendment Agreement reducing the aggregate gross proceeds to $500,000. The transaction closed on this date.
Outlook, Risks, and Management Commentary
- Strategic Partnership: The Investor agreed to cause an entity they control to offer the Company the opportunity to provide pharmaceutical cold chain logistics services in the Chengdu area and throughout China.
- Restrictions: The Shares are subject to a one-year restrictive period with an appropriate legend affixed to the certificate.
- Regulatory Status: The securities were issued in reliance on the exemption from Section 5 of the Securities Act of 1933 under Rule 506 of Regulation D, as the Investor is an accredited investor.
- Risks: The filing does not explicitly list new risk factors beyond the standard restrictions on the newly issued shares.
Investor Verification Checklist
- Verify the final closing price of $1.19 per share against the 120% premium formula based on the five-day average prior to closing.
- Confirm the exact number of outstanding shares to validate the 3.1% ownership stake calculation.
- Review the attached Amendment Agreement (Exhibit 10.1) for specific terms regarding the reduced purchase price and any other modified conditions.
- Assess the likelihood and terms of the proposed pharmaceutical cold chain logistics services in China.